UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2373-1
Program Prior Authorization/Medical Necessity
Medication Ctexli™ (chenodiol)
P&T Approval Date 6/2025
Effective Date 9/1/2025
1. Background:
Ctexli (chenodiol) is a bile acid indicated for treatment of cerebrotendinous xanthomatosis
(CTX) in adults.
2. Coverage Criteriaa:
A. Initial Authorization
1. Ctexli will be approved based on all of the following criteria:
a. Diagnosis of cerebrotendinous xanthomatosis (cholestanol storage disease)
-AND-
b. Disease is confirmed by the presence of pathogenic variant(s) in the CYP27A1 gene
-AND-
c. Prescribed by or in consultation with one of the following:
(1) Endocrinologist
(2) Geneticist
(3) Neurologist
Authorization will be issued for 12 months.
B. Reauthorization
1. Ctexli will be approved based on both of the following criteria:
a. Documentation of positive clinical response to Ctexli therapy
-AND-
b. Prescribed by or in consultation with one of the following:
(1) Endocrinologist
(2) Geneticist
(3) Neurologist
© 2025 UnitedHealthcare Services, Inc.
1
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
4. Reference:
1. Ctexli [package insert]. Foster City, CA: Mirum Pharmaceuticals, Inc.; July 2024.
2. Stelten BML, Dotti MT, Verrips A, Elibol B, Falik-Zaccai TC, Hanman K, Mignarri A, Sithole B,
Steiner RD, Verma S, Yahalom G, Zubarioglu T, Mochel F, Federico A. Expert opinion on
diagnosing, treating and managing patients with cerebrotendinous xanthomatosis (CTX): a modified
Delphi study. Orphanet J Rare Dis. 2021;16(1):353. doi:10.1186/s13023-021-01980-5.
3. DeBarber A, Kisanuki Y, Nobrega P, Himes R, Jayadev S, Bernat J, Prakash V, Gibson J, Larson A,
Sgobbi P, Murphy E, Fedor B, Wong Po Foo C, Dutta R, Imperiale M, Garner W, Vig P, Perez S,
Ramdhani R, Saute J, Duell PB. Evaluation of Chenodeoxycholic Acid Treatment in Adult Patients
with Cerebrotendinous Xanthomatosis: A Randomized, Placebo-Controlled Phase 3 Study [abstract].
Program Prior Authorization/Medical Necessity - Ctexli (chenodiol)
Change Control
6/2025 New program.
© 2025 UnitedHealthcare Services, Inc.
2